Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. [electronic resource]
Producer: 20070830Description: 457-64 p. digitalISSN:- 0006-4971
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Amyloidosis -- diagnosis
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Drug-Related Side Effects and Adverse Reactions
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin Light Chains -- immunology
- Male
- Middle Aged
- Predictive Value of Tests
- Prospective Studies
- Risk Factors
- Survival Rate
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.